All articles tagged with #xenotransplantation
A 66-year-old man, Tim Andrews, survived 271 days with a genetically modified pig kidney at Massachusetts General Hospital before receiving a human donor organ. This case, detailed in The Lancet, demonstrates xenotransplantation as a viable bridge therapy for patients awaiting human kidneys, addressing the critical organ shortage.
A 66-year-old patient at Mass General Brigham survived 271 days on a genetically engineered pig kidney, setting a new record for xenotransplantation. The organ served as a bridge to a human transplant, demonstrating that animal organs can safely sustain patients while they wait for human donors. This success supports the expansion of clinical trials for end-stage kidney disease.
A genetically modified pig kidney kept a 66-year-old man off dialysis for 271 days, marking the longest successful xenotransplant on record. The organ eventually failed, but the patient successfully received a human donor kidney afterward. This case supports the use of animal organs as a 'bridge' to human transplants, with expanded trials planned for 2027.
A 66-year-old man with end-stage kidney disease survived for a record 271 days using a genetically modified pig kidney, successfully bridging the gap to a human donor transplant. Published in The Lancet, the case confirms that xenografts can prevent dialysis-related deterioration without compromising future human organ acceptance. While the pig kidney eventually failed due to vascular damage, the patient received a human kidney in January 2026 with no adverse immune reactions. This milestone supports the expansion of clinical trials, with eGenesis planning to treat 33 patients across the US by 2027.
A 66-year-old US man, Tim Andrews, survived 271 days with a genetically modified pig kidney, setting a new record for xenotransplantation. The organ acted as a bridge, freeing him from dialysis until it failed, after which he received a human donor kidney. This milestone supports the use of pig organs to bridge the gap in the severe US organ shortage.
Russia has launched a $26 billion state program, New Health Preservation Technologies, to push longevity through gene therapy, lab-grown organs, and xenotransplantation using mini-pigs, led by Putin allies Maria Vorontsova and Mikhail Kovalchuk. While officials tout breakthroughs, critics say peer-reviewed results are scarce and sanctions complicate Western collaboration, underscoring the regime’s desire to preserve power amid aging elite and rising mortality concerns.
A 53-year-old brain-dead man received a genetically modified pig liver and two pig kidneys. The organs functioned for about five days; the liver started bile production within 19 hours and kidney function normalized, suggesting feasibility. However, within 36 hours signs of rejection appeared as pig cells were replaced by human cells and inflammatory markers rose, indicating the need for immune-targeted therapies. The pig had six genome edits (three human genes added, three pig genes removed) to reduce rejection, marking a major step toward addressing organ shortages while highlighting ongoing challenges in long-term compatibility.
A Gothamist item claims Vladimir Putin is reportedly overseeing an effort to grow human replacement organs inside mini-pigs, a controversial claim tied to longevity research.
Putin leads a $26 billion longevity initiative focused on bio-printing tissues and growing human organs inside mini-pigs, with his daughter Maria Vorontsova and physicist Mikhail Kovalchuk at the helm; early milestones include bioprinted cartilage and a mouse thyroid, with a goal of human organ replacement by the decade's end, though some scientists question the lack of peer‑reviewed validation.
A 56-year-old man with liver failure was connected to an externally perfused, genetically modified pig liver to keep him alive while awaiting a human liver transplant. The pig organ, engineered with six genetic changes to reduce rejection, functioned as a bridge for a few days; the patient subsequently received a human liver and is recovering. Researchers note the need for more details and that results should be published in a peer-reviewed journal.
Nature highlights seven technologies set to shape 2026, from xenotransplantation using CRISPR-edited animal organs to reduce immune rejection, to AI-powered weather forecasting and climate modelling, a renewed push in next-generation nuclear power including small modular reactors and fusion, and advances in light-microscopy brain mapping alongside a massive Vera C. Rubin Observatory sky survey that will catalog billions of celestial objects over a decade—portending gains in medicine, energy, climate science, neuroscience, and astronomy.
Tim Andrews, one of the first recipients of a genetically modified pig kidney, has now received a human kidney after the pig organ failed, marking a historic step in xenotransplantation and illustrating its potential to address organ shortages and reduce dialysis. Researchers are refining immunosuppressive regimens and planning additional xenotransplants as trials move forward.
Tim Andrews—one of the first recipients of a genetically modified pig kidney—has now received a human kidney, becoming the first in that small group to cross from animal to human organ. The pig kidney lasted 271 days before rejection, after which he returned to dialysis; days later he underwent a near-perfectly matched human kidney transplant. The case highlights xenotransplantation as a potential bridge to address the organ shortage, with ongoing research to refine immunosuppression and improve graft survival and plans for additional trials.
Scientists are making progress in transplanting genetically modified pig kidneys into humans to address organ shortages, despite ethical debates about creating human-like animals and the risks involved. The article discusses the scientific advancements, ethical concerns about animal welfare and moral status, and the regulatory history surrounding the use of animal organs and chimeras.
A leading surgeon, Dr. Robert Montgomery, discusses the potential of pig organ transplants, which have been gene-edited to reduce rejection, as a promising solution to the organ shortage crisis, with initial trials showing positive results and the possibility of future improvements making pig organs potentially superior to human ones.